COVID-19
Pfizer
The Food and Drug Administration
Moderna
BioNTech
FDA
variants.___The Associated Press Health and Science Department
the Howard Hughes Medical Institute’s Department of Science Education
AP
Ugur Sahin
Peter Marks
No matching tags
No matching tags
No matching tags
Pfizer
U.S.
No matching tags
So researchers gave a third shot to more than 1,600 youngsters — from age 6 months to 4 years — during the winter surge of the omicron variant.In a press release, Pfizer and its partner BioNTech said the extra shot did the trick, revving up tots’ levels of virus-fighting antibodies enough to meet FDA criteria for emergency use of the vaccine with no safety problems.Preliminary data suggested the three-dose series is 80% effective in preventing symptomatic COVID-19, the companies said, but they cautioned the calculation is based on just 10 cases diagnosed among study participants by the end of April.
As said here by LAURAN NEERGAARD